<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03394365</url>
  </required_header>
  <id_info>
    <org_study_id>ATA129-EBV-302</org_study_id>
    <nct_id>NCT03394365</nct_id>
  </id_info>
  <brief_title>Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) After Failure of Rituximab or Rituximab and Chemotherapy</brief_title>
  <acronym>ALLELE</acronym>
  <official_title>Multicenter, Open Label, Phase 3 Study of Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Subjects With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure of Rituximab or Rituximab and Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Atara Biotherapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Atara Biotherapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the clinical benefit and characterize the safety
      profile of tabelecleucel for the treatment of Epstein-Barr virus-associated post-transplant
      lymphoproliferative disease (EBV+ PTLD) in the setting of (1) solid organ transplant (SOT)
      after failure of rituximab and rituximab plus chemotherapy or (2) allogeneic hematopoietic
      cell transplant (HCT) after failure of rituximab.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, open-label, phase 3 study to assess the efficacy and safety of
      tabelecleucel for the treatment of EBV+ PTLD in the setting of SOT after failure of rituximab
      and rituximab plus chemotherapy (SOT cohort) or HCT after failure of rituximab (HCT cohort).

      Enrollment will be preceded by confirmation of availability of partially human leukocyte
      antigen (HLA) matched and restricted tabelecleucel for the participant.

      Study procedures and product administration will be the same for each cohort. Tabelecleucel
      will be administered in cycles lasting 5 weeks (35 days). During each cycle, participants
      will receive intravenous tabelecleucel at a dose of 2×10^6 cells/kg on Days 1, 8, and 15,
      followed by observation through Day 35. Treatment will continue until maximal response,
      unacceptable toxicity, initiation of non protocol therapy, or failure of tabelecleucel with
      up to 2 different HLA restrictions (SOT cohort) or up to 4 different HLA restrictions (HCT
      cohort).

      This protocol has been amended to include the HCT cohort from clinical study ATA129-EBV-301
      (NCT03392142).

      NOTE, 29 April 2020: Enrollment is temporarily paused at study site/locations with status
      &quot;active, not recruiting&quot; due to COVID-19 restrictions.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 29, 2017</start_date>
  <completion_date type="Anticipated">November 2020</completion_date>
  <primary_completion_date type="Anticipated">November 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>Yes</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate (ORR) in the SOT or HCT cohort</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR) in SOT and HCT cohorts separately</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ORR and DOR in SOT and HCT cohorts combined</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rates of complete response (CR) and partial response (PR)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to response</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to best response</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rates of allograft loss or rejection episodes (SOT cohort)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">66</enrollment>
  <condition>Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD)</condition>
  <condition>Solid Organ Transplant Complications</condition>
  <condition>Lymphoproliferative Disorders</condition>
  <condition>Allogeneic Hematopoietic Cell Transplant</condition>
  <condition>Stem Cell Transplant Complications</condition>
  <arm_group>
    <arm_group_label>SOT cohort -Subgroup A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants who have failed rituximab will receive IV tabelecleucel.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SOT cohort -Subgroup B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants who have failed both rituximab and chemotherapy will receive IV tabelecleucel.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HCT cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants who have failed rituximab will receive IV tabelecleucel.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>tabelecleucel</intervention_name>
    <description>Tabelecleucel is being investigated as an off-the-shelf, allogeneic T-cell immunotherapy for the treatment of EBV+ malignancies and diseases.</description>
    <arm_group_label>HCT cohort</arm_group_label>
    <arm_group_label>SOT cohort -Subgroup A</arm_group_label>
    <arm_group_label>SOT cohort -Subgroup B</arm_group_label>
    <other_name>tab-cel®</other_name>
    <other_name>ATA129</other_name>
    <other_name>EBV-CTL</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Prior SOT of kidney, liver, heart, lung, pancreas, small bowel, or any combination of
             these (SOT cohort); or prior allogeneic HCT (HCT cohort)

          2. A diagnosis of locally-assessed, biopsy-proven EBV+ PTLD

          3. Availability of appropriate partially HLA-matched and restricted tabelecleucel has
             been confirmed by the sponsor

          4. Measurable, 18F-deoxyglucose (FDG)-avid (Deauville score ≥ 3) systemic disease (using
             Lugano Classification response criteria by positron emission tomography
             (PET)-diagnostic computed tomography (CT), except when contraindicated or mandated by
             local practice, then magnetic resonance imaging (MRI) may be used.For subjects with
             treated central nervous system (CNS) disease, a head CT and/or brain/spinal MRI as
             clinically appropriate will be required to follow CNS disease response per Lugano
             Classification response criteria.

          5. Treatment failure of rituximab monotherapy (SOT cohort, subgroup A or HCT cohort) or
             rituximab plus chemotherapy (SOT cohort, subgroup B) for treatment of PTLD.

          6. Eastern Cooperative Oncology Group performance status ≤ 3 for subjects aged &gt; 16
             years; Lansky score ≥ 20 for subjects from birth to 16 years

          7. For HCT cohort only: If allogeneic HCT was performed as treatment for an acute
             lymphoid or myeloid malignancy, the underlying primary disease for which the subject
             underwent transplant must be in morphologic remission

          8. Adequate organ function

               1. Absolute neutrophil count ≥ 1000/μL, (SOT cohort) or ≥ 500/μL (HCT cohort), with
                  or without cytokine support

               2. Platelet count ≥ 50,000/μL, with or without transfusion or cytokine support. For
                  HCT cohort, platelet count &lt; 50,000/μL but ≥ 20,000/μL, with or without
                  transfusion support, is permissible if the subject has not had grade ≥ 2 bleeding
                  in the prior 4 weeks (where grading of the bleeding is determined per the
                  National Cancer Institute's Common Terminology Criteria for Adverse Events
                  [CTCAE], version 5.0)

               3. Alanine aminotransferase (ALT), aspartate aminotransferase (AST), and total
                  bilirubin (TBILI) each &lt; 5 × the upper limit of normal (ULN); however, ALT, AST,
                  and TBILI each ≤ 10 × ULN is acceptable if the elevation is considered by the
                  investigator to be due to EBV and/or PTLD involvement of the liver as long as
                  there is no known evidence of significant liver dysfunction (eg, elevated
                  prothrombin time due to liver dysfunction, signs/symptoms of liver dysfunction
                  such as asterixis, or similar).

          9. Subject or subject's representative is willing and able to provide written informed
             consent

        Exclusion Criteria:

          1. Burkitt lymphoma, classical Hodgkin lymphoma, or any T cell lymphoma

          2. Daily steroids of &gt; 0.5 mg/kg prednisone or glucocorticoid equivalent, ongoing
             methotrexate, or extracorporeal photopheresis

          3. Untreated CNS PTLD or CNS PTLD for which the subject is actively receiving
             CNS-directed chemotherapy (systemic or intrathecal) or radiotherapy at enrollment.
             NOTE:Subjects with previously treated CNS PTLD may enroll if CNS-directed therapy is
             complete.

          4. Suspected or confirmed grade ≥ 2 graft-versus-host disease (GvHD) per the Center for
             International Blood and Marrow Transplant Research (CIBMTR) consensus grading system
             at enrollment

          5. Ongoing or recent use of a checkpoint inhibitor agent (eg, ipilimumab, pembrolizumab,
             nivolumab) within 3 drug half-lives from the most recent dose to enrollment

          6. For HCT cohort: active adenovirus viremia

          7. Need for vasopressor or ventilatory support

          8. Antithymocyte globulin or similar anti-T cell antibody therapy ≤ 4 weeks prior to
             enrollment

          9. Treatment with Epstein-Barr virus cytotoxic T lymphocytes or chimeric antigen receptor
             (CAR) T cells directed against B cells within 8 weeks of enrollment (SOT or HCT
             cohorts), or unselected donor lymphocyte infusion within 8 weeks of enrollment (HCT
             cohort only)

         10. Female who is breastfeeding or pregnant or female of childbearing potential or male
             with a female partner of childbearing potential unwilling to use a highly effective
             method of contraception

         11. Inability to comply with study-related procedures
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Minoti Hiremath, MBBS, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Atara Biotherapeutics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Minoti Hiremath, MBBS, PhD</last_name>
    <phone>805-796-4080</phone>
    <email>clinicalstudies@atarabio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>City of Hope (Adults and Pediatrics)</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amandeep Salhotra, MD</last_name>
      <phone>626-256-4673</phone>
      <email>asalhotra@coh.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of California San Diego Moores Cancer Center (Adults only)</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Randy Taplitz, MD</last_name>
      <phone>858-822-6260</phone>
      <email>rtaplitz@ucsd.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Loma Linda University Cancer Center (Adults only)</name>
      <address>
        <city>Loma Linda</city>
        <state>California</state>
        <zip>92354</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Huynh Cao, MD</last_name>
      <phone>909-558-1000</phone>
      <email>hcao@llu.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>UCLA Medical Center (Adults and Pediatrics)</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Herbert Eradat, MD</last_name>
      <phone>310-633-8400</phone>
      <email>heradat@mednet.ucla.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of California Davis Comprehensive Cancer Center (Adults only)</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mehrdad Abedi, MD</last_name>
      <phone>916-703-9118</phone>
      <email>mabedi@ucdavis.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yale University (Adults and Pediatrics)</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06519</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pamela Valentino, MD</last_name>
      <phone>203-785-4649</phone>
      <email>pamela.valentino@yale.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lombardi Comprehansive Cancer Center (Adults and Pediatrics)</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Udeme Ekong, MD</last_name>
      <phone>202-444-3514</phone>
      <email>udeme.d.ekong@gunet.georgetown.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Florida (Adults and Pediatrics)</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Fort, MD</last_name>
      <phone>352-273-9120</phone>
      <email>john.fort@ufl.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Miami/Jackson Memorial Hospital (Adults only)</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amer Beitinjaneh, MD, MPH, MSc</last_name>
      <phone>305-243-6626</phone>
      <email>abeitinjaneh@miami.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's Healthcare of Atlanta at Egleston (Pediatrics)</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lakshmanan Krishnamurti, MD</last_name>
      <phone>404-785-1112</phone>
      <email>lakshmanan.krishnamurti@choa.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Winship Cancer Institute of Emory University (Adults only)</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jonathon Cohen, MD</last_name>
      <phone>404-778-3942</phone>
      <email>jonathon.cohen@emory.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ann &amp; Robert H. Lurie Children's Hospital of Chicago (Adults and Pediatrics)</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sonali Chaudhury, MD</last_name>
      <phone>312-227-4090</phone>
      <email>schaudhury@luriechildrens.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Chicago Medical Center - Duchossois Center for Advanced Medicine (Adults only)</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Satayaijt Kosuri, MD</last_name>
      <phone>773-702-7540</phone>
      <email>skosuri@medicine.bsd.uchicago.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Loyola University Medical Center (Adults and Pediatrics)</name>
      <address>
        <city>Maywood</city>
        <state>Illinois</state>
        <zip>60153</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick Stiff, MD</last_name>
      <phone>708-327-3148</phone>
      <email>pstiff@lumc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Maryland School of Medicine (Adults only)</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Saurabh Dahiya, MD</last_name>
      <phone>410-328-1230</phone>
      <email>sdahiya@umm.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute, Brigham and Women's Hospital (Adults and Pediatrics)</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Nikiforow, MD</last_name>
      <phone>617-632-6640</phone>
      <email>sarah_nikiforow@dfci.harvard.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine (Adults only)</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Armin Ghobadi, MD</last_name>
      <phone>314-747-8439</phone>
      <email>arminghobadi@wustl.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center (Adults only)</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ioannis Mantzaris, MD</last_name>
      <phone>718-910-4826</phone>
      <email>imantzar@montefiore.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center (Pediatrics only)</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center (Adults and Pediatrics)</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ran Reshef, MD</last_name>
      <phone>212-342-0530</phone>
      <email>rr3036@cumc.columbia.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center (Adults and Pediatrics)</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Prockop, MD</last_name>
      <phone>212-639-6715</phone>
      <email>prockops@mskcc.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center (Adults and Pediatrics)</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marcie Riches, MD, MS</last_name>
      <phone>919-966-7746</phone>
      <email>marcie_riches@med.unc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Carolinas Medical Center/Levine Children's Hospital (Adults and Pediatrics)</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philip Roehrs, MD</last_name>
      <phone>704-381-9900</phone>
      <email>philip.roehrs@carolinashealthcare.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Duke Cancer Institute (Adults only)</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew McKinney, MD</last_name>
      <phone>919-684-8111</phone>
      <email>matthew.mckinney@duke.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nationwide Children's Hospital (Pediatrics only)</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>The Ohio State University - Arthur G. James Cancer Center Hospital (Adults and Pediatrics)</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Baiocchi, MD, PhD</last_name>
      <phone>614-293-3196</phone>
      <email>robert.baiocchi@osumc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University Physicians Pavilion (Adults and Pediatrics)</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nemecek Eneida, MD</last_name>
      <phone>503-494-0829</phone>
      <email>nemeceke@ohsu.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia (Pediatrics only)</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nancy Bunin, MD</last_name>
      <phone>215-590-2255</phone>
      <email>buninn@email.chop.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania (Adults only)</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center (Adults only)</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rafic Farah, MD</last_name>
      <phone>412-864-6600</phone>
      <email>farahr@upmc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina (Adults and Pediatrics)</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Hudspeth, MD</last_name>
      <phone>843-792-8912</phone>
      <email>hudspeth@musc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saint Jude Children's Research Hospital (Pediatrics only)</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ashok Srinivasan, MD</last_name>
      <phone>901-595-4720</phone>
      <email>ashok.srinivasan@stjude.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vanderbilt - Ingram Cancer Center (Adults and Pediatrics)</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gowri Satyanarayana, MD</last_name>
      <phone>615-875-6138</phone>
      <email>gowri.satyanarayana@vanderbilt.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center - Children's Medical Center (Pediatrics only)</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dev Desai, MD</last_name>
      <phone>214-456-6277</phone>
      <email>dev.desai@utsouthwestern.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Baylor Scott and White Research Institute (Adults only)</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luis Pineiro, MD</last_name>
      <phone>214-370-1000</phone>
      <email>luisp@baylorhealth.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center (Adults and Pediatrics)</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kris Michael Mahadeo, MD</last_name>
      <phone>713-792-6620</phone>
      <email>kmmahadeo@mdanderson.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Froedtert Hospital &amp; the Medical College of Wisconsin (Adults only)</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Westmead Hospital (Adults only)</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shyam Panicker, MD, MBBS, MRCP, FRACP, FRCPA</last_name>
      <phone>+61 (2) 9845 6352</phone>
      <email>shyam.panicker@health.nsw.gov.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Prince Charles Hospital (Adults only)</name>
      <address>
        <city>Chermside</city>
        <state>Queensland</state>
        <zip>4032</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Chambers, MBBS, MRCP, FRACP, MD</last_name>
      <phone>+61 (7) 3139 4000</phone>
      <email>daniel.chambers@health.qld.gov.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fiona Stanley Hospital (Adults only)</name>
      <address>
        <city>Murdoch</city>
        <state>Western Australia</state>
        <zip>6150</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Duncan Purtill, MD, MBBS, FRACP, FRCPA</last_name>
      <phone>+61 (8) 6152 4139</phone>
      <email>duncan.purtill@health.wa.gov.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medizinische Universitat Wien (Adults only)</name>
      <address>
        <city>Wien</city>
        <zip>1091</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nina Worel, MD</last_name>
      <phone>+43 (1) 40400 54990</phone>
      <email>nina.worel@meduniwien.ac.at</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Hebrón - Institut de Recerca</name>
      <address>
        <city>Barcelona</city>
        <zip>8035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pere Barba, MD</last_name>
      <phone>+93 746 6100</phone>
      <email>pbarba@vhio.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Virgen del Rocio (Adults and Pediatrics)</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose Perez-Simon, MD</last_name>
      <phone>34-955 013260</phone>
      <email>josea.perez.simon.sspa@juntadeandalucia.es</email>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>December 29, 2017</study_first_submitted>
  <study_first_submitted_qc>January 4, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 9, 2018</study_first_posted>
  <last_update_submitted>July 24, 2020</last_update_submitted>
  <last_update_submitted_qc>July 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Epstein-Barr Virus (EBV)-associated Lymphoproliferative Disease (LPD)</keyword>
  <keyword>Epstein-Barr Virus (EBV)</keyword>
  <keyword>Cytotoxic T lymphocyte (CTL)</keyword>
  <keyword>Cancer After Transplant</keyword>
  <keyword>Kidney transplant</keyword>
  <keyword>Renal transplant</keyword>
  <keyword>Liver transplant</keyword>
  <keyword>Heart transplant</keyword>
  <keyword>Lung transplant</keyword>
  <keyword>Intestinal transplant</keyword>
  <keyword>Pancreas transplant</keyword>
  <keyword>Post-transplant Lymphoma</keyword>
  <keyword>Solid Organ Transplant (SOT)</keyword>
  <keyword>Bone Marrow Transplant Complications</keyword>
  <keyword>Epstein-Barr Virus-specific Cytotoxic T Lymphocytes (EBV-CTL)</keyword>
  <keyword>Hematopoietic Cell Transplant (HCT)</keyword>
  <keyword>Hematopoietic Stem Cell Transplantation (HSCT)</keyword>
  <keyword>Allogeneic Hematopoietic Cell Transplant</keyword>
  <keyword>Allogeneic, Off-The-Shelf T-cell Immunotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoproliferative Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

